ASKELA
ActiveSummary
ASKELA has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €291,736 and a net result of €28,346. Equity is growing by about 10% per year across the filed financial years. Its solvency ranks better than 95% of 22,536 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
23-07
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
31-12
Financial
Liquidity more than 6 timescurrent ratio 123.30
Current ratio from 19.66 to 123.30; short-term debt falls from €8,693 to €1,558.
26-08
NBB filing
Annual accounts filed
financial year 2024 · micro format · 26 days late
2024
31-12
Financial
Highest result from 2019 to 2025net €37,672 ▲1.6%
Net result €37,672, the highest in the series.
31-12
Financial
Liquidity more than doubledcurrent ratio 19.66
Current ratio from 8.53 to 19.66; short-term debt falls from €16,485 to €8,693.
31-01
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
27-07
Gazette deed
Resignations: Paul RANSART (manager) and PHARMACOACH (manager)Appointments: Paul RANSART (director) and PHARMACOACH (director) · Permanent representative: Stéphanie THOMAES · Amendment of the articles17 facts ▸
Gazette deed
Resignations: Paul RANSART (manager) and PHARMACOACH (manager)
Appointments: Paul RANSART (director) and PHARMACOACH (director) · Permanent representative: Stéphanie THOMAES · Amendment of the articles17 facts ▸
- General meeting, 10-07-2023
- Other provision, 0835.952.928, “BE835.952.928” (deed in French)
- Amendment of the articles (2 times)
- Capital conversion, “compte de capitaux propres statutairement indisponible” (deed in French)
- Reserve release, “disponibles pour distribution” (deed in French)
- Name change, ASKELA
- Other provision, “dispense de lecture du rapport sur modification d'objet, dispense le président de donner lecture” (deed in French)
- Capital
- Director resignation, Paul RANSART (manager)
- Director resignation, PHARMACOACH (manager)
- Director appointment, Paul RANSART (director (not named in the articles))
- Director appointment, PHARMACOACH (director (not named in the articles))
- +5 further facts in this act
30-06
Financial
Equity above €200,000equity €225,718 ▲19.7%
3 profitable years in a row build equity to €225,718.
31-01
NBB filing
Annual accounts filed
financial year 2022 · micro format
2021
09-02
NBB filing
Annual accounts filed
financial year 2020 · micro format · 9 days late
2020
30-06
Financial
Back to profitnet €5,332
Net result €5,332 after one loss-making year.
18-02
NBB filing
Annual accounts filed
financial year 2019 · micro format · 18 days late
Show earlier events
2019
13-02
NBB filing
Annual accounts filed
financial year 2018 · micro format · 13 days late
2018
19-02
NBB filing
Annual accounts filed
financial year 2017 · micro format · 19 days late
2017
27-02
NBB filing
Annual accounts filed
financial year 2016 · full format · 27 days late
2016
29-02
NBB filing
Annual accounts filed
financial year 2015 · full format · 29 days late
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 13 annual accounts filed, the latest 10 are here; all 13 are under Financials.
1 of 3 deeds read
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.